BioCentury
ARTICLE | Company News

Novavax, Fielding Pharmaceutical Co., King deal

January 2, 2001 8:00 AM UTC

NOX granted KG an exclusive license to its cell line technology to develop recombinant human papillomavirus (HPV) virus-like particle (VLP) vaccines. NOX retains the right to co-market resulting products in the U.S., and will receive a 17 percent royalty. As part of the agreement, NOX received $20 million through a convertible debenture investment by KG. The note is convertible into NOX shares at $10 and carries a 4 percent coupon payable semi-annually in cash and stock. NOX is eligible to receive an additional $5 million convertible debt investment upon filing an NDA for its Estrasorb topical transdermal estrogen replacement therapy, which is expected in the first half of 2001. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article